Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.

被引：3
|
作者：
Goyal, Lipika [1 ]
Meric-Bernstam, Funda [2 ]
Hollebecque, Antoine [3 ]
Morizane, Chigusa [4 ]
Valle, Juan W. [5 ]
Karasic, Thomas B. [6 ]
Abrams, Thomas A. [7 ]
Kelley, Robin Kate [8 ]
Cassier, Philippe [9 ]
Furuse, Junji [10 ]
Klumpen, Heinz-Josef [11 ]
Chang, Heung-Moon [12 ]
Chen, Li-Tzong [13 ]
Komatsu, Yoshito [14 ]
Masuda, Kunihiro [15 ]
Ahn, Daniel [16 ]
He, Yaohua [17 ]
Soni, Nital [18 ]
Benhadji, Karim A. [17 ]
Bridgewater, John A. [19 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Manchester, Manchester, Lancs, England
[6] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Ctr Leon Berard, Lyon, France
[10] Kyorin Univ, Tokyo, Japan
[11] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[12] Asan Med Ctr, Seoul, South Korea
[13] Natl Inst Canc Res, Tainan, Taiwan
[14] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[15] Tohoku Univ, Sendai, Miyagi, Japan
[16] Mayo Clin, Phoenix, AZ USA
[17] Taiho Oncol Inc, Princeton, NJ USA
[18] Taiho Oncol, Princeton, NJ USA
[19] UCL, Canc Inst, London, England
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT010
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF PEMIGATINIB FOR PATIENTS WITH ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA AND FGFR2 FUSIONS/ REARRANGEMENTS: 2024 FIGHT-202 TRIAL FINAL RESULTS
    Huang, W. M.
    Wang, I. T.
    Chen, H. L.
    Chueh, C. H.
    Chiang, N. J.
    Tsai, Y. W.
    VALUE IN HEALTH, 2024, 27 (12)
  • [42] Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection
    Buckarma, EeeLN
    De La Cruz, Gabriel
    Truty, Mark
    Nagorney, David
    Cleary, Sean
    Kendrick, Michael
    Borad, Mitesh
    Graham, Rondell P.
    Gores, Gregory
    Smoot, Rory
    HPB, 2022, 24 (10) : 1748 - 1756
  • [43] ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
    Mazzaferro, Vincenzo
    El-Rayes, Bassel F.
    Cotsoglou, Christian
    Harris, William Proctor
    Damjanov, Nevena
    Masi, Gianluca
    Rimassa, Lorenza
    Personeni, Nicola
    Braiteh, Fadi S.
    Zagonel, Vittorina
    Papadopoulos, Kyriakos P.
    Hall, Terence
    Wang, Yunxia
    Abbadessa, Giovanni
    Schwartz, Brian E.
    Kazakin, Julia
    Busset, Michele Droz Dit
    Shaib, Walid La Bib
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Xu, Jianming
    Xiong, Jianping
    Gu, Shanzhi
    Niu, Zuoxing
    Yin, Fei
    Sun, Beicheng
    Zhang, Lan
    Zhou, Fuxiang
    Hao, Chunyi
    Pan, Yueyin
    Qiu, Wensheng
    Gao, Yi
    Ren, Yongxin
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review
    Washburn, Leslie
    Mahipal, Amit
    Jatoi, Aminah
    Kottschade, Lisa
    Tran, Nguyen
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2627 - 2636
  • [46] Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: An exploration of response to systemic therapy
    Bibeau, Kristen
    Feliz, Luis
    Barrett, Scott
    Na, Ling
    Lihou, Christine Francis
    Asatiani, Ekatherine
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] Global Expanded Access Program (EAP) to pemigatinib for patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements
    Lindley, Anouk
    Prager, Gerald
    Bitzer, Michael
    Burn, Timothy C.
    Lihou, Christine F.
    Richards, Elisabeth Croft
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 82 - 82
  • [48] Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
    Bensi, M.
    Giannarelli, D.
    Bagala, C.
    Niger, M.
    Bergamo, F.
    Barone, D.
    Rizzato, M. D.
    Nichetti, F.
    Spring, A.
    De Rosa, A.
    Beccia, V.
    Ricagno, G.
    Pircher, C. C.
    Ardito, F.
    Barbaro, B.
    Giuliante, F.
    Martinelli, E.
    De Braud, F. G. M.
    Lonardi, S.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S229 - S229
  • [49] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Park, J. O.
    Cassier, P. A.
    Kamath, S. D.
    Meng, D. T. Wai
    Dotan, E.
    Kim, R.
    Sahai, V.
    Oh, D-Y.
    Liao, C-Y.
    Millward, M.
    Perez, D. Roda
    Ferte, C.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1381 - S1381
  • [50] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Park, J. O.
    Meng, D. T. Wai
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Cassier, P.
    Kamath, S. D.
    Dotan, E.
    Kim, R.
    Sahai, V.
    Liao, C-Y.
    Millward, M.
    Roda Perez, D.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1461 - S1462
12345